Form 4 for NTLA Intellia Therapeutics, Inc.
Accepted 2026-08-24 16:05:04 ET · period of report 2026-08-20 · accession 0001193125-26-363567 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-24 16:05 | 2026-08-20+ | NTLA | LEONARD JOHN M | Pres, CEO, Dir | S - Sale | $12.65 | -22.7K | 1.15M | -2% | -$286.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-20 | S | D | 19,890 | $12.60 | 1,149,849 | D | — | — | (F1) The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.32 to $13.00, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 20, 2026 at each separate price. |
| 2 | Common | Common Stock | 2026-08-21 | S | D | 2,785 | $13.00 | 1,147,064 | D | — | — | (F1) The sales reported on this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2026. |